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What we already know
Cytochrome P450 (CYP450), sulfotransferase (SULT), and
glucuronidase (UGT) enzymes play roles in the phase I and
phase II metabolism of most clinically prescribed drugs. As
polymorphisms in these genes may alter enzyme activities,
most prescribed drugs will differ in their efficacy and side
effects. In prior work, we showed that besides polymorphisms
in CYP450, those in SULT and UGT also give rise to different
serum levels of some drug metabolites than detected in wild-
type carriers of the genes [1]. To date, most pharmacogenetic
studies have examined Asian and Caucasian populations and
although the pharmacogenetics of CYP450 genes has been
explored in sub-Saharan countries, scarce data exist for
African genetic variations in SULT and UGT [2, 3].
Africans show an extremely high incidence of malaria,
tuberculosis, and HIV/AIDS, along with a growing rate of
noncommunicable diseases, especially diabetes, and
hypertension [4]. Data concerning these diseases and others
indicate a wide diversity of prevalence and mortality rates
among African countries. Although therapeutic drugs have
improved life expectancies in many countries, most drugs
have been associated with adverse drug reactions (ADRs)
[4]. As CYP450 enzymes metabolize antiretrovirals, anti-
malarials, and antipsychotics, knowledge of their genetic
variability could be useful for clinicians. In some developed
countries, a high economic burden of deaths has been
attributed to ADRs whereas no such estimates exist for
African populations. This lack of data highlight a need to
improve knowledge on ADRs in Africa, mainly when these
effects are associated with drugs used to treat the main
killer diseases in this continent. Knowledge such as this is
essential to develop and implement pharmacogenetic tests
both in developing and developed countries.
Africans show the broadest genetic variability of all
human populations. This is because the African origin of
mankind has meant a longer time period for genetic diver-
sity in Africans compared to non-Africans. For example,
according to known CYP450 variability, 90% of clinically
relevant CYP2C8, CYP2C19, and CYP2D6 variants occur
within the range of 0–24% [5]. North African ethnicities
have been largely overlooked regarding the detection of
genes involved in drug metabolism such as SULTs and
UGTs. Besides their genetic variability, African populations
are characterized by their remarkable linguistic and cultural
diversity, consistent with the huge diversity of landscapes
and habitats of this continent. Current North African cul-
tures (from Morocco to Egypt) have an ancient Berber
background with influences from several civilizations of
different historical times. The Arabs settled permanently in
North Africa and although they persuaded Berbers to adopt
Islam, some large Berber groups in Morocco, Algeria, and
Tunisia have retained their Berber language and customs
and avoided mixed marriages until today. Prior studies of
the genetic variability of these North African groups have
detected vast genetic heterogeneity and a lack of genetic
groupings by either geographical or linguistic criteria [6].
This considerable genetic variability has been previously
reported for CYP3A4, CYP3A5, SULT1A1, SULT1A2, and
SULT1E1 in North African populations [7].
Here, we stress the importance of assessing the fre-
quencies of CYPs, SULTs, and UGTs in North African
populations because of their role in the metabolism of many
drugs and their association with various types of cancer. In
ongoing work, we have been looking at the UGT mutations
UGT1A4 Pro24Thr (rs6755571), UGT1A4 Leu48Val
(rs2011425), UGT2B7 His268Tyr (rs7439366), UGT2B15
Asp85Tyr (rs1902023), UGT2B15 Lys523Thr (rs4148269),
and UGT2B17del in populations from Morocco, Libya,
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Tunisia, and Algeria. Some variants seem to confer reduced
UGT activity, for instance, the UGT2B1585Tyr allele in
response to oxazepam and lorazepam and UGT1A448Val and
UGT2B7268Tyr with effects on tamoxifen metabolism [8, 9].
In contrast, no effects of the UGT2B17 deletion have been
detected on oxazepam and androgenic steroid substrate
availability, perhaps owing to the possible duplication event
origin of UGT2B15 and UGT2B17, which show similar
sequence identity [10].
North African populations
The groups examined in this work underway comprise the
general population representative of two Moroccan Berber
localities (Asni region in the High Atlas and Sidi Bouhria in
the northeast Atlas), one Algerian Berber region and dif-
ferent areas of Tunisia and Libya. Four hundred and eighty-
four DNA samples—collected from healthy, unrelated
individuals (both sexes) aged 18–60 years and native to the
regions they lived in (at least three generations)—were
processed as previously described [7]. All subjects signed
an informed consent form approved by the ethics commit-
tees of the Universities responsible for sample collection
(Chouaib Doukkali University in Morocco, Monastir
University in Tunisia, and Abderrahmane Mira Bejaia
University in Algeria). Individuals from Tunisia and Libya
were Arabic speaking, whereas the Moroccan and Algerian
subjects sampled spoke Berber.
UGT polymorphisms
The allelic variants UGT1A424Thr, UGT1A448Val,
UGT2B7268Tyr, UGT2B1585Tyr, UGT2B15523Thr, and
UGT2B17del were genotyped as described in Romero-Lorca
et al. [9] using conventional quantitative polymerase chain
reaction and polymerase chain reaction-restriction fragment
length polymorphism techniques. Allele frequencies were
estimated through direct gene counts. Hardy–Weinberg
equilibrium was assessed using an exact test. North African
data were compared with data available for European and
Sub-Saharan African populations from the 1000Genomes
database (http://www.1000Genomes.org) using the pairwise
population differentiation test included in Arlequin v.3.5
(http://cmpg.unibe.ch/software/arlequin35/). Genetic diver-
sities were estimated using Nei’s formula [11].
Allele frequencies of the UGT polymorphisms are pro-
vided in Table 1. All genes examined were in
Hardy–Weinberg equilibrium. Compared with European
and Sub-Saharan African samples, the Moroccan samples
show higher UGT1A448Val and UGT2B7268Tyr allele fre-
quencies (0.260 and 0.464, respectively, Table 1). Pairwise
population differences highlight differentiation between the
two Nigerian samples and North Africans and Europeans
for all markers except UGT1A448Val. With regard to the
internal heterogeneity of North African samples, Libya was
the population showing the lowest average genetic diversity
(0.242), whereas northeast Atlas Morocco showed the
highest diversity (0.373). Greatest population differentiation
was observed for UGT1A448Val, UGT2B7268Tyr, and
UGT2B17del, mainly owing to their frequencies in northeast
Atlas Moroccans, Tunisians, and Libyans. These results are
in agreement with our published data for CYP and SULT
polymorphisms, which also largely exceeded the variation
ranges described for European populations [7].
Associated risks or functional roles
The association between some gene polymorphisms and the
presence of functional role- or risk associated phenotypes is
Table 1 Allele frequencies of UGT1A4 Pro24Thr, UGT1A4 Leu48Val, UGT2B7 His268Tyr, UGT2B15 Asp85Tyr, UGT2B15 Lys523Thr,

























0.057 0.052 0.054 0.027 0.067 0.042 0.051 0.060 0.000 0.010
UGT1A448Val
rs2011425
0.080 0.260 0.048 0.025 0.144 0.089 0.159 0.071 0.083 0.101
UGT2B7268Tyr
rs7439366
0.464 0.250 0.372 0.086 0.186 0.450 0.520 0.530 0.210 0.240
UGT2B15523Thr
rs4148269
0.605 0.500 0.518 0.576 0.558 0.621 0.617 0.648 0.106 0.136
UGT2B1585Tyr
rs1902023
0.430 0.452 0.415 0.357 0.394 0.514 0.495 0.456 0.569 0.581
UGT2B17del 0.039 0.315 0.072 0.174 0.244 No data available in 1000Genomes project
Data from the 1000Genomes project are also provided for European population groups (Iberians, Italians, and British) and for African samples
from Nigeria (Yoruba in Ibadan and Esan). Sample sizes indicated between parentheses
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a relevant issue when studying such diverse groups as North
African populations. Given marked differences in CYP,
SULT, and UGT polymorphisms between Caucasian and
Sub-Saharan African groups and their relevance both in
drug pharmacogenetics and risks of various types of cancer,
detailed study of the frequencies of these mutations is
needed to improve clinical decision-making in African
healthcare institutions. In prior work, we detected a 2–3
times higher frequency of CYP3A4*1B associated with
prostate cancer in North Africans compared with European
Caucasians (Table 2), peaking at 29% in Moroccan Berbers
[7]. Some SULT gene alleles are also important because of
both their link to endometrial cancer and their high fre-
quency in some areas of North Africa. For instance, the
SULT1A1*2 allele appears in ~ 50% of northeast Atlas
Moroccan Berbers (Table 2) [7].
Given these marked ethnic differences in CYP and SULT
genes and their association with drug pharmacogenetics and
disease risk, UGT gene polymorphisms must also be con-
sidered in population studies because of their known
influence in the metabolism of some drugs such as lor-
azepam and tamoxifen [8, 9]. The higher frequency of the
UGT1A448Val mutation (26% in some Moroccan areas;
Table 1) relative to those reported in Caucasians is espe-
cially remarkable. Indeed, the wt homozygous genotype
UGT1A4Leu/Leu has been linked to a better efficacy of
lamotrigine (epileptic drug used in pediatric patients) [12].
The UGT2B1585Tyr allele, which appears in up to 45% of
individuals in some North African areas, is a high-activity
allele possibly associated with a reduced prostate cancer
risk according to increased rates of androgen glucuronida-
tion leading to lower intraprostate androgen levels (Table 2)
[13]. It has also been reported that patients homozygous for
the UGT2B1585Tyr mutation show a significantly lower
mean apparent oral oxazepam clearance rate compared with
wt/wt patients [14]. The UGT2B17 allele deletion appeared
at a rate worth considering though within the reported range
for other populations despite the variation observed among
ethnic groups, e.g., rates of 21% and 33%, respectively,
described for African Americans and Caucasians [15].
Women with both copies of the UGT2B17 gene deletion
show an increased risk of lung adenocarcinoma associated
with decreased NNAL (tobacco-specific metabolite of
nitrosamine) glucuronidation rates [16]. Further, a reduced
risk of colorectal cancer has been described in Caucasian
men homozygous for UGT2B17del [17]. This last link has
been related to the preferred metabolism of UGT2B17 over
that of certain nonsteroidal anti-inflammatory drugs and
over flavonoids with antioxidant properties, such that indi-
viduals lacking UGT2B17 may have higher levels of these
protective dietary components [17].
The variation ranges of CYP, SULT, and UGT genes
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higher than those reported for European Caucasians. Given
the known links of some of these polymorphisms both with
ADRs and the risk of some cancer types, studies are
urgently needed to improve knowledge of the prevalence
of these allelic variants. Future studies are also required
to examine the impact of these genetic variants on different
drugs in terms of their availability, metabolism, and effi-
cacy. This will be a good starting point to develop
pharmacogenetic tests for use in clinical practice that will
avoid unnecessary costs to healthcare systems. The infor-
mation arising from these studies will have useful impli-
cations for healthcare professionals both in developing
countries and in other countries when managing patients
of North African origin.
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